Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
Provider: ValuEngine, Inc.
Provider: Reuters Investment Profile
Provider: Wright Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genmab A/S Maintains FY 2013 Financial Guidance

Tuesday, 7 May 2013 01:02am EDT 

Genmab A/S announced that the Company's fiscal year 2013 financial guidance remains unchanged. The Company continues to expect fiscal year 2013 revenue of between DKK 540 million and DKK 580 million, and operating loss from continuing operations of between DKK 40 million and DKK 90 million for the period. According to I/B/E/S Estimates analysts on average are expecting Genmab to report operating profit of negative DKK 40.00 million for the fiscal year 2013. 

Company Quote

20 Apr 2015